Closed Loop Medicine recruits first patient into clinical trial for patients with high blood pressure
Closed Loop Medicine (CLM), a clinical stage therapeutics company developing drug + digital combination products, announces that the first patient has been recruited into its pivotal clinical trial investigating CLM’s integrated precision care solution for patients with hypertension.
Cell Guidance Systems introduces Exo-spin 96 exosome purification kit
Cell Guidance Systems Ltd, a specialist in exosome research reagents and services, today announced the launch of a new product for the purification of exosomes from blood and other samples. The Exo-spin™ 96 exosome purification kit allows researchers to purify exosome samples in the standard 96 well plate format.
Bicycle Therapeutics reports third quarter 2020 financial results and provides corporate update
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycles®) technology, today reported financial results for the third quarter ended September 30, 2020 and discussed recent corporate updates.
Babraham Research Campus seeks independent non-executive directors to help set future strategy and development of the campus
Babraham Bioscience Technologies (BBT), which is responsible for the management and commercial development of the Babraham Research Campus, today announced two new Board positions.
Accelerate@Babraham Start-up Programme underway with four new life science start-ups taking part in five month programme
The Babraham Research Campus’ third cohort of Accelerate@Babraham life science start-ups came together yesterday (Monday) for the first day of the 2020/21 programme.
Atelerix awarded Innovate UK funding to enable transport and storage of cellular therapies at room temperature
Atelerix Ltd, pioneers in the storage and transport of cells at room temperature, has received a significant award under the UK Innovation and Science Seed Fund (UKI2S) Accelerator Programme from Innovate UK, the UK’s innovation agency. The funding will support the development of room temperature solutions for shipping therapeutic cells, as part of the company’s “BloodReady” project.
Reflection Therapeutics secures Innovate UK co-funding for major research programme to fight motor neurone disease through cell therapy
Reflection Therapeutics, Cambridge-based developer of cell therapy against neuroinflammation, is pleased to announce the start of a major Innovate Smart Grant project co-funded by Innovate UK, the UK’s innovation agency.
Closed Loop Medicine secures £250,000 Innovate UK continuity funding
Closed Loop Medicine has secured £250,000 from Innovate UK to support clinical evaluation of a drug + digital combination product for hypertension and COVID- 19 monitoring.
New report confirms Babraham Research Campus at the forefront in supporting the UK’s early-stage bioscience enterprises
Research led by an academic team from the University of Cambridge has demonstrated the benefits and outputs from the significant taxpayer investment into the Babraham Research Campus; evidencing the overall economic, social and scientific contribution the Campus makes to the UK economy.
Mission moves to new Babraham Campus headquarters
Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announces its move to new purpose-built headquarters on the Babraham Research Campus, Cambridge.
Eisai pledges its support for the Babraham Research Campus’ Accelerate@Babraham initiative
Eisai joins AstraZeneca, LifeArc and Mundipharma in providing funding towards the continued development of the Babraham Research Campus bio-incubator programme, supporting early-stage science and new life science companies within the Cambridge cluster.
Application deadline extended for programme to support early stage life science ventures
Applications for Accelerate@Babraham, designed to support early stage life science ventures, will close on June 17th 2020.
Biotech rises to COVID-19 testing challenge
A drug discovery business has announced that it will soon be able to complete 15,000 COVID-19 diagnostic tests per month in a bid to help the country combat the virus.
LifeArc ‘Accelerate@Babraham Award’ for most progressed venture awarded to CC Bio and Reflection Therapeutics
Two start-up ventures share the inaugural LifeArc ‘Accelerate @Babraham Award'.
PolyProx Therapeutics raises an additional £1m seed financing to validate polyproxin® drug leads in oncology
PolyProx Therapeutics, a biotechnology company focused on the discovery and development of novel biopharmaceuticals for the treatment of cancer, today announces that it has raised an additional £1 million seed capital from new investor, LifeArc.
Babraham Investor Conference calls for companies
Babraham Investor Conference (BIC) is a must attend one-day conference for investors focusing on early-stage and scale-up life science and med-tech companies from across the UK and Europe.
Mission and AbbVie’s collaboration in Alzheimer’s and Parkinson’s diseases reaches milestone
Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), and AbbVie, a global, research-driven biopharmaceutical company, have announced the identification of several DUBs as potential drug targets in their Alzheimer’s and Parkinson’s R&D collaboration.
Babraham Research Campus accelerator programme attracts further sponsorship to support early-stage science ventures
Mundipharma joins AstraZeneca and LifeArc in providing funding for the continued development of the ‘Accelerate@Babraham’ initiative .
Accelerate@Babraham attracts additional sponsorship to boost innovation in Cambridge life science cluster
LifeArc joins AstraZeneca in providing funding towards the continued development of the Babraham Research Campus’ Accelerate@Babraham initiative, which aims to nurture the development of early-stage science concepts and new life science companies.
Accelerate@Babraham Start-up Competition 2019: winners announced
Five science start-ups have been awarded £10k, access to the Babraham Research Campus bio-incubator facilities, Accelerate@Babraham, and will receive an extended programme of mentoring and support.
Babraham Investor Conference 2019 - registration closes 10th May
Babraham Investor Conference (BIC) is a must attend one-day conference for investors focusing on early-stage and scale-up life science and med-tech companies from across the UK and Europe. It takes place on Wednesday 15th May 2019 at the Babraham Research Campus, Cambridge, UK.
Dr James Summers appointed to Mission Therapeutics’ Board of Directors
Mission Therapeutics, a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), has announced the appointment of Dr James Summers as an independent member to its Board of Directors, with immediate effect.
PolyProx Therapeutics raises £3.4m seed financing to validate novel class of cancer drugs
PolyProx Therapeutics, a new biotechnology company focused on the discovery and development of novel biopharmaceuticals for the treatment of cancer, today announced that it has raised £3.4m of seed capital.
Kadans Science Partner takes first step into Cambridge and UK life science market
Kadans enters the UK life science market by acquiring, from Imperial College ThinkSpace, the B900 building located on the Babraham Research Campus (BRC) in Cambridge, adding to its Pan-European science park portfolio.
PredictImmune’s first prognostic test for IBD launches in the UK and Ireland
The world’s first validated prognostic test for inflammatory bowel disease (IBD) is now available via Cambridge University Hospitals NHS Foundation Trust’s Genomic Laboratory Hub.